Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

31.60 +0.24 (+0.77%)
Streaming Delayed Price Updated: 10:39 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Changes to Executive Management Team
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Settles Price Fixing Charges With U.S. DOJ
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reports Second Quarter 2023 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
News headline image
Teva Concludes Nationwide Opioids Settlement Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
From Phil Inc.
Via Business Wire
News headline image
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Launches New “Pivot to Growth” Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Launch New Growth Strategy at Investor Day
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Complete Response Letter Received for AVT02 Biologics License Application
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.